Principal Financial Group Inc. Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Principal Financial Group Inc. grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 40.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 258,495 shares of the medical equipment provider's stock after purchasing an additional 74,149 shares during the quarter. Principal Financial Group Inc. owned approximately 0.38% of Lantheus worth $25,229,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Summit Securities Group LLC bought a new position in shares of Lantheus during the 4th quarter valued at about $37,000. UMB Bank n.a. boosted its holdings in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after acquiring an additional 381 shares during the period. Blue Trust Inc. boosted its holdings in Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after acquiring an additional 633 shares during the period. 1620 Investment Advisors Inc. purchased a new stake in Lantheus during the 4th quarter valued at about $125,000. Finally, GAMMA Investing LLC boosted its holdings in Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock valued at $128,000 after acquiring an additional 298 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on LNTH. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Truist Financial dropped their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, B. Riley dropped their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $130.50.

Lantheus Trading Up 1.3%

NASDAQ LNTH traded up $1.12 on Thursday, hitting $84.61. The company's stock had a trading volume of 173,392 shares, compared to its average volume of 1,023,673. Lantheus Holdings, Inc. has a 52-week low of $73.11 and a 52-week high of $126.89. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. The company's 50-day simple moving average is $81.25 and its 200 day simple moving average is $90.06. The firm has a market cap of $5.85 billion, a P/E ratio of 23.96 and a beta of 0.12.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The company's quarterly revenue was up .8% compared to the same quarter last year. During the same quarter last year, the business posted $1.69 EPS. Research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares in the company, valued at $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.50% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.